A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer
Phase of Trial: Phase I/II
Latest Information Update: 17 Apr 2018
At a glance
- Drugs H 1PV (Primary) ; H 1PV (Primary)
- Indications Pancreatic cancer
- Focus Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms ParvOryx02
- Sponsors Oryx GmbH & Co
- 11 Apr 2018 Planned End Date changed from 1 Jul 2017 to 1 Sep 2018.
- 11 Apr 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2018.
- 10 Jun 2017 Biomarkers information updated